The U.S. Food and Drug Administration published a new draft guidance to highlight fundamental considerations to researchers investigating the use of psychedelic drugs for potential treatment of medical conditions, including psychiatric or substance use disorders....
Ann Wieben, a UW Clinical Trials Institute colleague, discusses her research on the use of machine learning/artificial intelligence in nursing. Ann is a clinical research program specialist at UW Health and a Ph.D. candidate in the UW–Madison School of Nursing....
The UW Health | Carbone Cancer Center and UW Program for Advanced Cell Therapy, or PACT, will soon begin a clinical trial using a recently developed cell therapy to treat severe dry mouth....
New initiatives at UW Health seek to highlight and streamline patient access to individualized, data-driven cancer care....
The UW Clinical Trials Institute (CTI) will implement a budget template in support of a consistent clinical trials budgeting experience for industry sponsors across SMPH and UW Health....
Investigators will be assessing the use of the drug to treat impaired social motivation, or asociality, which is a symptom of schizophrenia that can cause significant functional impairment....
According to UW–Madison geriatrician Nathaniel Chin, "We are on a trajectory for prevention."...
UW Health and the UW School of Medicine and Public Health (SMPH) have convened a new committee to help centralize and streamline the clinical trials review process at UW–Madison....
With new support from the National Institutes of Health, a team of researchers at the Wisconsin Institute of Discovery will lead drug therapeutics testing for two diseases known to cause blindness....
A drug used in people in the early stage of the most common kind of breast cancer – HR+/HER2- breast cancer – significantly reduced the risk of the cancer returning after treatment, according to a new study....
